N4 Pharma Plc (AIM: N4P), provide details of its work plan following the encouraging data from its oncology research as announced on 13 December 2021. The company sounded very positive with the update released this week.
Share talk spoke with Nigel Theobald, covering the latest announcement and asking him about the market response to news being released by the company, current share price and how often do they have to update the markets?
Have you fully funded all current work streams in Q1/2 in 2022, yes we have more than sufficient funds to carry out the work planned, just a few of the topics raised in the podcast.
https://www.share-talk.com/nigel-theobald-chief-executive-officer-n4-pharma-plc-lonn4p-interview/
https://www.share-talk.com/nigel-theobald-chief-executive-officer-n4-pharma-plc-lonn4p-interview/
Listen On
Also Listen
-
Zak Mir talks to Ippolito Cattaneo, Chief Executive Officer of Ajax Resources Plc
Zak Mir talks to Ippolito Cattaneo, CEO of Ajax Resources, in the wake of this w -
Zak Mir talks to Segun Lawson, President & CEO of Thor Explorations
Zak Mir talks to Segun Lawson, President & CEO of Thor Explorations, in the wake -
Zak Mir talks to Howard White, Interim Chairman, Hydrogen Utopia International
Zak's Traders Cafe spoke with Howard White, interim chairman of Hydrogen Utopia -
Panther Metals (LON: PALM) Bitcoin, Tailings, and a High-Conviction Pivot
In a recent conversation with Zak Mir from Zak’s Traders Café, Panther Metals CE